Clinical Trial Update: A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating the HSP90 inhibitor AT13387 alone or in combination with abiraterone acetate for prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• AT13387 (AT13387)
• Abiraterone acetate (Abiraterone acetate)

Snippet

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED